GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Renal Associates Holdings Inc (NYSE:ARA) » Definitions » WACC %

American Renal Associates Holdings (American Renal Associates Holdings) WACC % :7.3% (As of May. 11, 2024)


View and export this data going back to 2016. Start your Free Trial

What is American Renal Associates Holdings WACC %?

As of today (2024-05-11), American Renal Associates Holdings's weighted average cost of capital is 7.3%%. American Renal Associates Holdings's ROIC % is 0.00% (calculated using TTM income statement data). American Renal Associates Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


American Renal Associates Holdings WACC % Historical Data

The historical data trend for American Renal Associates Holdings's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Renal Associates Holdings WACC % Chart

American Renal Associates Holdings Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
WACC %
Get a 7-Day Free Trial - 7.36 6.51 6.79 9.39

American Renal Associates Holdings Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.45 9.39 7.92 7.15 6.56

Competitive Comparison of American Renal Associates Holdings's WACC %

For the Diagnostics & Research subindustry, American Renal Associates Holdings's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Renal Associates Holdings's WACC % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Renal Associates Holdings's WACC % distribution charts can be found below:

* The bar in red indicates where American Renal Associates Holdings's WACC % falls into.



American Renal Associates Holdings WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, American Renal Associates Holdings's market capitalization (E) is $397.939 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Sep. 2020, American Renal Associates Holdings's latest one-year quarterly average Book Value of Debt (D) is $740.4666 Mil.
a) weight of equity = E / (E + D) = 397.939 / (397.939 + 740.4666) = 0.3496
b) weight of debt = D / (E + D) = 740.4666 / (397.939 + 740.4666) = 0.6504

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.5%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. American Renal Associates Holdings's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.5% + 1 * 6% = 10.5%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Sep. 2020, American Renal Associates Holdings's interest expense (positive number) was $41.288 Mil. Its total Book Value of Debt (D) is $740.4666 Mil.
Cost of Debt = 41.288 / 740.4666 = 5.5759%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -9.62 / 24.796 = -38.8%, which is less than 0%. Therefore it's set to 0%.

American Renal Associates Holdings's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.3496*10.5%+0.6504*5.5759%*(1 - 0%)
=7.3%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Renal Associates Holdings  (NYSE:ARA) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, American Renal Associates Holdings's weighted average cost of capital is 7.3%%. American Renal Associates Holdings's ROIC % is 0.00% (calculated using TTM income statement data). American Renal Associates Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

American Renal Associates Holdings (American Renal Associates Holdings) Business Description

Traded in Other Exchanges
N/A
Address
500 Cummings Center, Suite 6550, Beverly, MA, USA, 01915
American Renal Associates Holdings Inc is a joint venture-focused dialysis services provider in the United States. The company through its subsidiary is engaged in providing kidney dialysis services for patients suffering from chronic kidney failure, also known as end-stage renal disease. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure.
Executives
Don E Williamson officer: EVP, Chief Operating Officer 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Victoria Labriola officer: VP and General Counsel AMERICAN RENAL HOLDINGS, INC. 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Joseph A Carlucci director, officer: Chief Executive Officer C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Syed T Kamal director, officer: President C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Jeremy Gelber director C/O CENTERBRIDGE PARTNERS, L.P., 375 PARK AVE, 12TH FLOOR, NEW YORK NY 10152
Christopher J Hocevar director 1601 CHESTNUT STREET SHAREHOLDER SERVICES TL05Y PHILADELPHIA PA 19192
Robert H Fish director C/O SKILLED HEALTHCARE 27442 PORTOLA PARKWAY, SUITE 200 FOOTHILL RANCH CA 92610
Michael Boxer director 9151 BOULEVARD 26 NORTH RICHLAND HILLS TX 76180
John M Jureller director FRONTIER COMMUNICATIONS, 401 MERRITT 7, NORWALK CT 06851
Thomas W Erickson director OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Jason Boucher officer: Former VP & CFO 500 CUMMINGS CENTER SUITE 6550 BEVERLY MA 01915
Mark Herbers officer: Interim CFO and Interim CAO 500 CUMMINGS CENTER, SUITE 6550, BEVERLY MA 01915
Michael Ray Costa officer: VP and General Counsel C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Patrick T Ryan director 401 EDGEWATER PLACE, SUITE 500, WAKEFIELD MA 01880
Jonathan L Wilcox officer: VP & Chief Financial Officer C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915

American Renal Associates Holdings (American Renal Associates Holdings) Headlines

From GuruFocus